Does asialoerythropoietin exert stronger angiogenic activity than erythropoietin via its binding affinity to tissue?
AEPO exerts stronger angiogenic effects than those of EPO presumably via its tissue affinity. Administration of AEPO is a promising option for the treatment of patients with critical limb ischemia.
baPWV was associated with the composite coronary and carotid atherosclerotic burden in a community-based asymptomatic population.